| 10.99 0.87 (8.6%) | 03-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.1 |
1-year : | 15.3 |
| Resists | First : | 11.21 |
Second : | 13.1 |
| Pivot price | 10.32 |
|||
| Supports | First : | 10.27 |
Second : | 9.69 |
| MAs | MA(5) : | 10.22 |
MA(20) : | 10.29 |
| MA(100) : | 9.12 |
MA(250) : | 6.4 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 45 |
D(3) : | 30 |
| RSI | RSI(14): 61.5 |
|||
| 52-week | High : | 11.21 | Low : | 2.59 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DSGN ] has closed below upper band by 0.4%. Bollinger Bands are 23% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.22 - 11.26 | 11.26 - 11.29 |
| Low: | 10.1 - 10.15 | 10.15 - 10.19 |
| Close: | 10.91 - 10.98 | 10.98 - 11.04 |
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Mon, 16 Mar 2026
Design Therapeutics (NASDAQ:DSGN) Sees Unusually-High Trading Volume - Time to Buy? - MarketBeat
Mon, 16 Mar 2026
Design Therapeutics (NASDAQ:DSGN) Now Covered by Jefferies Financial Group - MarketBeat
Mon, 16 Mar 2026
Jefferies initiates Design Therapeutics stock with buy on drug potential - Investing.com
Tue, 10 Mar 2026
Piper Sandler reiterates Overweight on Design Therapeutics stock - Investing.com
Tue, 10 Mar 2026
Design Therapeutics (NASDAQ:DSGN) Rare Disease Research In Nasdaq Today - Kalkine Media
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 57 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 35.9 (%) |
| Held by Institutions | 67.3 (%) |
| Shares Short | 1,800 (K) |
| Shares Short P.Month | 2,320 (K) |
| EPS | -1.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.5 % |
| Return on Equity (ttm) | -29.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.02 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -52 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -9.24 |
| PEG Ratio | 0 |
| Price to Book value | 3.13 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|